Chinese biotech BeiGene raises $903 million in Hong Kong’s first secondary listing under new rules – sources

The listing comes as Hong Kong works to lure overseas-listed firms to conduct secondary share offerings in the financial hub. It is also the second listing under new rules for early-state drug develop…
( read original story …)

---